Table of Contents: 1 Report Prologue 2 Market Introduction 2.1 Definition 2.2 Scope of Study 2.3 Research Objective 2.4 Assumptions & Limitations 2.4.1 Assumptions 2.4.2 Limitations 2.5 Market Structure 3 Research Methodology 3.1 Research Process 3.2 Primary Research 3.3 Secondary Research 4 Market Dynamics 4.1 Introduction 4.2 Drivers 4.2.1 Increasing Cancer Survival Rate 4.2.2 Growing Demand for Advanced Therapies 4.2.3 Less Number of Side Effects as Compared to Conventional Treatment Methods 4.2.4 Growth of Cancer Healthcare Facilities in Emerging Countries 4.2.5 Changing Lifestyle and Increasing Smoking Population in Middle East & Africa 4.3 Restraints 4.3.1 High cost of Cancer Biological Therapy 4.4 Opportunities 4.4.1 UnTapped Types of Cancers 5 Market Factor Analysis 5.1 Porter’s Five Forces Model 5.1.1 Bargaining power of suppliers 5.1.2 Bargaining Power of Buyers 5.1.3 Threat of New Entrants 5.1.4 Threat of Substitutes 5.1.5 Intensity of Rivalry 6 Global Cancer Biological Therapy Market, by phases 6.1 Introduction 6.2 Phases 7 Global Cancer Biological Therapy Market, by Application 7.1 Introduction 7.2 Monoclonal Antibodies 7.3 Interferons 7.4 Interleukins 7.5 Cancer growth inhibitors 7.6 Gene Therapy 7.7 Colony-Stimulating Factors 8 Global Cancer Biological Therapy Market, by End Users 8.1 Introduction 8.2 Hospitals & Clinics 8.3 Cancer Research Centers 8.4 Laboratories 9 Global Cancer Biological Therapy Market, by Region 9.1 Introduction 9.2 North America 9.2.1 US 9.2.2 Canada 9.3 Europe 9.3.1 Germany 9.3.2 France 9.3.3 U.K. 9.3.4 Italy 9.3.5 Spain 9.3.6 Rest of Europe 9.4 Asia-Pacific 9.4.1 Japan 9.4.2 China 9.4.3 India 9.4.4 Republic of Korea 9.4.5 Rest of Asia-Pacific 9.5 Middle East & Africa 9.5.1 Middle East 9.5.2 Africa 12 Competitive Landscape 12.1 Company Share Analysis 13 Company Profiles 13.1 Amgen Inc. 13.1.1 Company Overview 13.1.2 Product/Business Overview 13.1.3 Adherium Health: Financials 13.1.4 Key Developments 13.1.5 SWOT Analysis 13.2 Bristol-Myers Squibb 13.2.1 Company Overview 13.2.2 Product overview 13.2.3 Financial Overview 13.2.4 Key Developments 13.2.5 SWOT Analysis 13.3 Celgene Corporation 13.3.1 Company Overview 13.3.2 Product Overview 13.3.3 Financial Overview 13.3.4 Key Development 13.3.5 SWOT Analysis 13.4 ELI Lilly and Company 13.4.1 Company Overview 13.4.2 Product Overview 13.4.3 Financial Overview 13.4.4 Key Developments 13.4.5 SWOT Analysis 13.5 EnGeneIC Ltd 13.5.1 Company Overview 13.5.2 Product overview 13.5.3 Financial Overview 13.5.4 Key Developments 13.5.5 SWOT Analysis

List of Tables: TABLE 1 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 2 MONOCLONAL ANTIBODIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2014-2023 (USD MILLION) TABLE 3 INTERFERONS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION) TABLE 4 INTERLEUKINS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION) TABLE 5 CANCER GROWTH INHIBITORS FOR CANCER BIOLOGIC THERAPY MARKET, BY REGION 2014-2023 (USD MILLION) TABLE 6 GENE THERAPY FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION) TABLE 7 COLONY STIMULATING FACTOR FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION) TABLE 8 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 9 HOSPITALS & CLINICS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION) TABLE 10 CANCER RESEARCH CENTERS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION) TABLE 11 LABORATORIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION) TABLE 12 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION) TABLE 13 NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2014-2023 (USD MILLION) TABLE 14 NORTH AMERICA BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 15 NORTH AMERICA BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 16 U.S. CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 17 U.S. CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 18 CANADA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 19 CANADA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 20 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2014-2023 (USD MILLION) TABLE 21 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 22 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 23 GERMANY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 24 GERMANY CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 25 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 26 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 27 U.K. CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 28 U.K. CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 29 ITALY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 30 ITALY CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 31 SPAIN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 32 SPAIN CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 33 ROE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 34 ROE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 35 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2014-2023 (USD MILLION) TABLE 36 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 37 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 38 JAPAN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 39 JAPAN CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 40 CHINA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 41 CHINA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 42 INDIA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 43 INDIA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 44 REPUBLIC OF KOREA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 45 REPUBLIC OF KOREA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 46 ROA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 47 ROA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 48 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION) TABLE 49 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 50 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 51 MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 52 MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 53 AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION) TABLE 54 AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION) TABLE 55 AMGEN INC.: KEY DEVELOPMENTList of Figures: FIGURE 1 RESEARCH PROCESS FIGURE 2 MARKET DYNAMICS FOR GLOBAL CANCER BIOLOGICAL THERAPY MARKET FIGURE 3 ATTRITION RATE OF PHASE III CLINICAL TRIALS IN EUROPE, 2012 (%) FIGURE 4 CANCER BIOLOGICAL THERAPY SUCCESS RATES IN VARIOUS PHASES OF CLINICAL TRIALS FIGURE 5 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY TYPE 2016 FIGURE 6 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY END USER, 2016 FIGURE 7 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY REGION, 2016 FIGURE 8 NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2016 FIGURE 9 EUROPE CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2016 FIGURE 10 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2016 FIGURE 11 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2016 FIGURE 12 QATAR: CANCER INCIDENCE AND MORTALITY RATES (%) FIGURE 13 UAE: CANCER INCIDENCE AND MORTALITY RATES (%) FIGURE 14 KUWAIT: CANCER INCIDENCE AND MORTALITY RATES (%) FIGURE 15 BAHRAIN: CANCER INCIDENCE AND MORTALITY RATES (%) FIGURE 16 OMAN: CANCER INCIDENCE AND MORTALITY RATES (%) FIGURE 17 SAUDI ARABIA: CANCER INCIDENCE AND MORTALITY RATES (%) FIGURE 18 GLOBAL CANCER BIOLOGICAL THERAPY MARKET: COMPANY SHARE ANALYSIS, 2015 (%) FIGURE 19 AMGEN INC.: KEY FINANCIALS FIGURE 20 AMGEN INC.: SEGMENTAL REVENUE FIGURE 21 AMGEN INC.: GEOGRAPHICAL REVENUE FIGURE 22 BRISTOL-MYERS SQUIBB.: KEY FINANCIALS FIGURE 23 BRISTOL-MYERS SQUIBB.: SEGMENTAL REVENUE FIGURE 24 BRISTOL-MYERS SQUIBB: GEOGRAPHICAL REVENUE FIGURE 25 CELGENE CORPORATION.: KEY FINANCIALS FIGURE 26 CELGENE CORPORATION.: SEGMENTAL REVENUE FIGURE 27 CELGENE CORPORATION: GEOGRAPHICAL REVENUE FIGURE 28 ELI LILLY AND COMPANY.: KEY FINANCIALS FIGURE 29 ELI LILLY AND COMPANY.: SEGMENTAL REVENUE FIGURE 30 ELI LILLY AND COMPANY: GEOGRAPHICAL REVENUE FIGURE 31 F. HOFFMANN-LA ROCHE AG: FINANCIAL REVENUE FIGURE 32 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE FIGURE 33 F. HOFFMANN-LA ROCHE AG: GEOGRPAHICAL REVENUE FIGURE 34 MERCK & CO., INC: FINANCIAL REVENUE FIGURE 35 MERCK & CO., INC: SEGMENTAL REVENUE FIGURE 36 MERCK & CO., INC: GEOGRPAHICAL REVENUE FIGURE 37 NOVARTIS: FINANCIAL REVENUE FIGURE 38 NOVARTIS: SEGMENTAL REVENUE FIGURE 39 NOVARTIS: GEOGRPAHICAL REVENUE FIGURE 40 PFIZER INC: FINANCIAL REVENUE FIGURE 41 PFIZER INC: SEGMENTAL REVENUE FIGURE 42 PFIZER INC: GEOGRPAHICAL REVENUE

Merck Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Bristol-Myers Squibb, Celgene, ELI Lilly and Company, EnGeneIC, and Pfizer